Genelux (NASDAQ:GNLX) Director Sells $50,000.00 in Stock

Genelux Corporation (NASDAQ:GNLX) Director John Thomas sold 10,000 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $5.00, for a total value of $50,000.00. Following the sale, the director owned 492,784 shares in the company, valued at approximately $2,463,920. This trade represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Genelux Price Performance

Genelux stock opened at $4.65 on Friday. The business has a 50 day moving average of $5.72 and a 200-day moving average of $4.10. The company has a market capitalization of $176.93 million, a P/E ratio of -5.28 and a beta of 0.06. Genelux Corporation has a 1 year low of $1.99 and a 1 year high of $8.53.

Genelux (NASDAQ:GNLX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. Equities analysts anticipate that Genelux Corporation will post -0.88 EPS for the current year.

Institutional Trading of Genelux

A number of large investors have recently added to or reduced their stakes in the stock. Private Management Group Inc. purchased a new position in Genelux in the second quarter valued at about $33,000. Liberty Wealth Management LLC bought a new stake in shares of Genelux in the 1st quarter worth approximately $45,000. American Century Companies Inc. purchased a new position in Genelux in the first quarter valued at approximately $51,000. Beacon Capital Management LLC lifted its stake in Genelux by 99.8% in the second quarter. Beacon Capital Management LLC now owns 19,116 shares of the company’s stock valued at $55,000 after purchasing an additional 9,550 shares during the last quarter. Finally, Falcon Wealth Planning grew its holdings in Genelux by 83.3% during the second quarter. Falcon Wealth Planning now owns 22,000 shares of the company’s stock valued at $63,000 after purchasing an additional 10,000 shares during the period. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Loop Capital set a $16.00 target price on Genelux in a research report on Tuesday, October 21st. Lake Street Capital initiated coverage on Genelux in a research note on Tuesday, October 21st. They issued a “buy” rating and a $16.00 price target for the company. Maxim Group set a $20.00 price objective on Genelux in a research note on Tuesday, October 21st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.